Your session is about to expire
← Back to Search
Niraparib + TSR-042 for Endometrial Cancer
Study Summary
This trial is testing an investigational drug to see if it can help treat endometrial cancer that has come back or is advanced. The drug works by targeting a protein called PARP, and researchers want to see if it is more effective in patients whose cancer has a specific genetic change.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not taken hormonal therapy in the last 2 weeks.My brain metastases have been stable for a set period.I have been treated with PARP inhibitors or drugs targeting DNA repair.I had a severe reaction to previous immunotherapy, with some exceptions.I have had a fistula or am at high risk of developing one.I don't have severe side effects from previous cancer treatments.I have a history of HIV or active hepatitis.My organs and bone marrow are functioning normally.I have been treated with specific immunotherapy before.I have been on a stable dose of corticosteroids for at least 4 weeks.I can take care of myself and am up and about more than half of my waking hours.I have had a recent transfusion or major surgery.I have had pelvic radiotherapy within the specified time.I do not have any unmanaged ongoing illnesses.I haven't had chemotherapy or biologic agents in the last 4 weeks.I have not had a bowel obstruction in the last 3 months.I had cancer before, but it's been a while.I have a history of MDS or AML.I have a weakened immune system or a history of certain infections.I have a specific type of uterine cancer, not including certain rare forms.I have a history of lung scarring or fibrosis.I have not been diagnosed with an immune system problem or taken steroids in the last week.My cancer has worsened after my last treatment.I have had platinum-based chemotherapy before, and may have had hormone or immunotherapy.I can provide a previous tumor sample or am willing to have a biopsy for testing.I have not received a live vaccine in the last 14 days.
- Group 1: Niraparib +TSR-042
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does Niraparib come with any notable safety concerns?
"Our evaluation of Niraparib has deemed its safety to be a 2 on the 1-3 scale, as this is a Phase 2 trial. Consequently, there are data points that suggest it is safe yet no clinical evidence suggesting efficacy."
How widely is this research endeavor being conducted across North America?
"This trial is being held at 7 distinct medical sites, including Juravinski Cancer Centre in Hamilton, Cancer Centre of Southeastern Ontario at Kingston in Kingston and Princess Margaret Cancer Centre in Toronto. Additionally, 4 more facilities are participating."
Is there still an opportunity for participants to join this experiment?
"Recruitment for this trial has been concluded, with the last update to its page occurring on November 18th 2021. For those searching for other clinical trials involving endometrial neoplasms, there are currently 285 studies actively admitting participants and 115 that allow Niraparib as a treatment option."
To what extent have researchers explored the potential of Niraparib through clinical trials?
"Presently, 115 clinical trials are actively studying the efficacy of Niraparib with 14 in their final phase. These studies span 3320 locations globally, particularly concentrated around Washington D.C.."
How many participants are enrolled in this experiment?
"This research effort has since concluded its participant recruitment. The trial was initiated in November of 2017 and last updated in 18th 2021. Alternately, if you are interested in similar studies, there are currently 285 clinical trials recruiting for endometrial neoplasms and 115 clinical trials with Niraparib as the primary drug being studied."
What is the predominant application of Niraparib?
"Niraparib is typically used to treat primary peritoneal cancer, but has also been proven as an effective therapy for advanced mismatch repair-deficient (dmmr) endometrial cancer, disease that has progressed during or following platinum-containing chemotherapy and fallopian tubes cancer."
Share this study with friends
Copy Link
Messenger